Kaken Pharmaceutical Co (KKPCF) Income Statement
Kaken Pharmaceutical Co Income Statement
Last quarter (Q1 2026), Kaken Pharmaceutical Co's total revenue was $18.87B, an increase of 3.36% from the same quarter last year. In Q1, Kaken Pharmaceutical Co's net income was $271.00M. See Kaken Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| $ 94.03B | $ 76.87B | $ 72.04B | $ 72.98B | $ 76.03B | |
| $ 58.26B | $ 39.24B | $ 38.54B | $ 39.56B | $ 41.58B | |
| $ 37.23B | $ 40.14B | $ 29.03B | $ 31.55B | $ 24.51B | |
| Depreciation and Amortization | $ 2.55B | $ 3.33B | $ 2.75B | $ 2.57B | $ 2.48B |
| $ 22.02B | $ 5.68B | $ 12.57B | $ 9.40B | $ 16.38B | |
| $ 21.04B | $ -899.00M | $ 9.51B | $ 8.00B | $ 17.06B | |
| $ -1.60B | $ 3.21B | $ 283.00M | $ -1.18B | $ -3.18B | |
| $ 19.43B | $ 2.31B | $ 9.80B | $ 6.82B | $ 13.88B | |
| $ 13.95B | $ 2.14B | $ 8.03B | $ 5.44B | $ 9.55B | |
| Per Share Metrics | |||||
| Basic EPS | $ 365.42 | $ 56.55 | $ 212.66 | $ 144.79 | $ 251.44 |
| Diluted EPS | $ 365.42 | $ 56.55 | $ 212.66 | $ 144.79 | $ 251.44 |
| Weighted Average Shares Outstanding | 38.16M | 37.91M | 37.74M | 37.57M | 37.98M |
| Weighted Average Shares Outstanding (Diluted) | 38.16M | 37.91M | 37.74M | 37.57M | 37.98M |
Currency in JPY